Immix Biopharma Inc expected to post a loss of 23 cents a share - Earnings Preview
25/03/2025 20:15
Immix Biopharma Inc IMMX.OQ IMMX.O is expected to report resultson May 7 (estimated) for the period ending March 31 2025 LSEG's mean analyst estimate for Immix Biopharma Inc is for a loss of 23 cents per share. The one available analyst rating on the shares is "buy". The mean earnings estimate of analysts had fallen by about 78.6% in the last three months. Wall Street's median 12-month price target for Immix Biopharma Inc is $7.00, above its last closing price of $1.82. This summary was machine generated March 25 at 20:15 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Recent news on Immix Biopharma
See all newsBrief: Immix Biopharma Announces Closing Of $125 Million Underwritten Offering Of Common Stock
US RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Brief: Immix Biopharma Announces Pricing Of $125 Million Underwritten Offering Of Common Stock
Brief: Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary